|
Jan 11
|
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
|
|
Dec 27
|
13 Most Promising Small-Cap Stocks According to Analysts
|
|
Dec 8
|
Ligand (LGND) Up 12.4% Since Last Earnings Report: Can It Continue?
|
|
Dec 6
|
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
|
|
Dec 1
|
Here's Why Ligand Pharmaceuticals (LGND) is a Strong Value Stock
|
|
Dec 1
|
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
|
|
Nov 28
|
Tharimmune (THAR) Up on Positive Data From Pipeline Candidate
|
|
Nov 28
|
Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
|
|
Nov 28
|
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study
|
|
Nov 27
|
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
|
|
Nov 27
|
Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan
|
|
Nov 8
|
Compared to Estimates, Ligand (LGND) Q3 Earnings: A Look at Key Metrics
|
|
Nov 8
|
Ligand Pharmaceuticals Inc (LGND) Reports Q3 2023 Financial Results with Increased Revenue Guidance
|
|
Nov 8
|
Ligand Reports Third Quarter 2023 Financial Results
|
|
Nov 7
|
bluebird (BLUE) Q3 Earnings Top; Zynteglo, Skysona Fuel Sales
|
|
Nov 6
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
|
Nov 6
|
Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial
|
|
Nov 3
|
Bausch Health (BHC) Q3 Earnings & Sales Beat, '23 View Updated
|
|
Nov 3
|
Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised
|
|
Nov 3
|
ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues
|